FRM
LGND icon

Fox Run Management’s Ligand Pharmaceuticals LGND Stock Holding History

Fox Run Management’s Portfolio LGND Stock Details LGND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-5,391
Closed -$245K – 293
2020
Q1 		$245K Buy
+5,391
New +$306K 0.58% 52
2019
Q1 		– Sell
-4,820
Closed -$408K – 595
2018
Q4 		$408K Buy
+4,820
New +$514K 0.22% 175
2017
Q4 		– Sell
-3,046
Closed -$259K – 781
2017
Q3 		$259K Buy
+3,046
New +$241K 0.07% 540

Other funds holding LGND

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
CCMLC
Cardinal Capital Management LLC (Connecticut) Greenwich, Connecticut $365M AUM 18.32% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
CCA
Conestoga Capital Advisors Wayne, Pennsylvania $5.01B AUM 6.26% 1-Year Est. Return
SDJVC
St. Denis J. Villere & Co New Orleans, Louisiana $907M AUM 10.61% 1-Year Est. Return

Fox Run Management's LGND Position: Q2 2020 in Review

Fox Run Management sold out of Ligand Pharmaceuticals (LGND) in Q2 2020, closing a stake of 5,391 shares — an estimated $245K sold.

Fox Run Management first reported a position in LGND in Q3 2017 and held it in 3 quarters. The position peaked at $408K in Q4 2018. 262 funds tracked by Wall St. Rank hold LGND as of Q2 2020.

  • Fox Run Management reported no remaining Ligand Pharmaceuticals position as of Q2 2020 after selling out during the quarter.
  • Fox Run Management sold 5,391 Ligand Pharmaceuticals shares in Q2 2020, an estimated $245K.
  • Fox Run Management first reported a position in Ligand Pharmaceuticals in Q3 2017 and held it in 3 quarters.
  • Fox Run Management's Ligand Pharmaceuticals position peaked at $408K in Q4 2018.
  • 262 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q2 2020.

Based on Fox Run Management's 13F filing for Q2 2020, filed 31 Jul 2020.